Testing and Treatment of Males for Bacterial Vaginosis
Males should not be routinely tested or treated for bacterial vaginosis (BV), even when their female sexual partner tests positive. 1
Why Males Are Not Tested or Treated
The CDC guidelines are unequivocal on this matter: male sex partners of women with BV are not symptomatic, and treatment of male partners has not been shown to alter either the clinical course of BV in women during treatment or the relapse/recurrence rate 1. Therefore:
- No diagnostic testing exists for BV in males - BV is defined by vaginal flora changes (clue cells, vaginal pH >4.5, fishy odor, characteristic discharge) that cannot be assessed in males 1
- BV is not considered exclusively an STD - while associated with sexual activity, it represents an alteration in vaginal bacterial flora rather than a transmissible infection 1
- Routine treatment of sex partners is not recommended 1
Important Caveat: Recent Contradictory Evidence
However, a 2025 randomized controlled trial challenges this long-standing recommendation. The StepUp trial 2 found that treating male partners with combined oral and topical antimicrobial therapy significantly reduced BV recurrence in female partners:
- Recurrence rate with partner treatment: 35% (1.6 per person-year)
- Recurrence rate without partner treatment: 63% (4.2 per person-year)
- Absolute risk reduction: 2.6 recurrences per person-year (P<0.001)
The Regimen Used in the 2025 Study
When male partner treatment was studied, the regimen was:
- Metronidazole 400 mg orally twice daily for 7 days
- PLUS 2% clindamycin cream applied to penile skin twice daily for 7 days 2, 3
This combined approach was well-tolerated, with side effects limited to nausea, headache, and metallic taste 2. The topical component targets BV-associated bacteria on penile skin that may contribute to reinfection 3.
Clinical Decision-Making Algorithm
For standard practice (following current guidelines):
- Do not test the male partner
- Do not treat the male partner
- Treat only the female partner with standard BV therapy 1
For recurrent BV cases (≥3 episodes in 12 months):
- Consider discussing partner treatment as an off-label option based on the 2025 evidence 2
- If pursuing partner treatment, use the combined regimen: metronidazole 400 mg PO BID + clindamycin 2% cream topically BID, both for 7 days
- Counsel about the experimental nature of this approach and potential side effects
- Ensure both partners complete treatment simultaneously and avoid unprotected intercourse during treatment
Key Pitfalls to Avoid
- Do not prescribe single-agent oral metronidazole alone for male partners - the 2021 study 4 showed this approach was ineffective, while the successful 2025 trial 2 used combined oral and topical therapy
- Do not confuse BV with trichomoniasis - trichomoniasis DOES require partner treatment with metronidazole 2 g orally as a single dose 5, 6
- Recognize that older guidelines (1993,2002) predate the recent evidence - the 2025 trial 2 represents the highest quality and most recent evidence, though it contradicts established guidelines that have not yet been updated
Standard Female Treatment (For Reference)
The female partner should receive standard BV treatment 1:
- Preferred: Metronidazole 500 mg orally twice daily for 7 days (95% cure rate)
- Alternative: Metronidazole 2 g orally as single dose (84% cure rate)
- Advise avoiding alcohol during and 24 hours after metronidazole treatment
The evidence base is evolving, and the 2025 trial 2 provides compelling data that partner treatment may benefit women with recurrent BV, despite decades of guidelines recommending against it.